Literature DB >> 24354785

Deficiency of FK506-binding protein (FKBP) 51 alters sleep architecture and recovery sleep responses to stress in mice.

Stefana Albu1, Christoph P N Romanowski, M Letizia Curzi, Vladimira Jakubcakova, Cornelia Flachskamm, Nils C Gassen, Jakob Hartmann, Mathias V Schmidt, Ulrike Schmidt, Theo Rein, Florian Holsboer, Felix Hausch, Marcelo Paez-Pereda, Mayumi Kimura.   

Abstract

FK506-binding protein 51 (FKBP51) is a co-chaperone of the glucocorticoid receptor, functionally linked to its activity via an ultra-short negative feedback loop. Thus, FKBP51 plays an important regulatory role in the hypothalamic-pituitary-adrenocortical (HPA) axis necessary for stress adaptation and recovery. Previous investigations illustrated that HPA functionality is influenced by polymorphisms in the gene encoding FKBP51, which are associated with both increased protein levels and depressive episodes. Because FKBP51 is a key molecule in stress responses, we hypothesized that its deletion impacts sleep. To study FKBP51-involved changes in sleep, polysomnograms of FKBP51 knockout (KO) mice and wild-type (WT) littermates were compared at baseline and in the recovery phase after 6-h sleep deprivation (SD) and 1-h restraint stress (RS). Using another set of animals, the 24-h profiles of hippocampal free corticosterone levels were also determined. The most dominant effect of FKBP51 deletion appeared as increased nocturnal wake, where the bout length was significantly extended while non-rapid eye movement sleep (NREMS) and rapid eye movement sleep were rather suppressed. After both SD and RS, FKBP51KO mice exhibited less recovery or rebound sleep than WTs, although slow-wave activity during NREMS was higher in KOs, particularly after SD. Sleep compositions of KOs were nearly opposite to sleep profiles observed in human depression. This might result from lower levels of free corticosterone in FKBP51KO mice, confirming reduced HPA reactivity. The results indicate that an FKBP51 deletion yields a pro-resilience sleep phenotype. FKBP51 could therefore be a therapeutic target for stress-induced mood and sleep disorders.
© 2013 European Sleep Research Society.

Entities:  

Keywords:  FKBP51; depression; free corticosterone; rapid eye movement sleep; restraint stress; slow-wave activity

Mesh:

Substances:

Year:  2013        PMID: 24354785     DOI: 10.1111/jsr.12112

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  15 in total

Review 1.  Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications.

Authors:  Anthony S Zannas; Tobias Wiechmann; Nils C Gassen; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2015-08-13       Impact factor: 7.853

2.  A rodent model of traumatic stress induces lasting sleep and quantitative electroencephalographic disturbances.

Authors:  Michael T Nedelcovych; Robert W Gould; Xiaoyan Zhan; Michael Bubser; Xuewen Gong; Michael Grannan; Analisa T Thompson; Magnus Ivarsson; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  ACS Chem Neurosci       Date:  2015-01-28       Impact factor: 4.418

3.  Selective inhibitors of the FK506-binding protein 51 by induced fit.

Authors:  Steffen Gaali; Alexander Kirschner; Serena Cuboni; Jakob Hartmann; Christian Kozany; Georgia Balsevich; Christian Namendorf; Paula Fernandez-Vizarra; Claudia Sippel; Anthony S Zannas; Rika Draenert; Elisabeth B Binder; Osborne F X Almeida; Gerd Rühter; Manfred Uhr; Mathias V Schmidt; Chadi Touma; Andreas Bracher; Felix Hausch
Journal:  Nat Chem Biol       Date:  2014-12-01       Impact factor: 15.040

4.  Macrocyclic FKBP51 Ligands Define a Transient Binding Mode with Enhanced Selectivity.

Authors:  Andreas M Voll; Christian Meyners; Martha C Taubert; Thomas Bajaj; Tim Heymann; Stephanie Merz; Anna Charalampidou; Jürgen Kolos; Patrick L Purder; Thomas M Geiger; Pablo Wessig; Nils C Gassen; Andreas Bracher; Felix Hausch
Journal:  Angew Chem Int Ed Engl       Date:  2021-05-07       Impact factor: 15.336

5.  Dicholine succinate, the neuronal insulin sensitizer, normalizes behavior, REM sleep, hippocampal pGSK3 beta and mRNAs of NMDA receptor subunits in mouse models of depression.

Authors:  Brandon H Cline; Joao P Costa-Nunes; Raymond Cespuglio; Natalyia Markova; Ana I Santos; Yury V Bukhman; Aslan Kubatiev; Harry W M Steinbusch; Klaus-Peter Lesch; Tatyana Strekalova
Journal:  Front Behav Neurosci       Date:  2015-02-26       Impact factor: 3.558

6.  Depletion of FKBP51 in female mice shapes HPA axis activity.

Authors:  Lianne Hoeijmakers; Daniela Harbich; Bianca Schmid; Paul J Lucassen; Klaus V Wagner; Mathias V Schmidt; Jakob Hartmann
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

7.  Repeated Systemic Treatment with Rapamycin Affects Behavior and Amygdala Protein Expression in Rats.

Authors:  Martin Hadamitzky; Arne Herring; Julia Kirchhof; Ivo Bendix; Matthew J Haight; Kathy Keyvani; Laura Lückemann; Meike Unteroberdörster; Manfred Schedlowski
Journal:  Int J Neuropsychopharmacol       Date:  2018-06-01       Impact factor: 5.176

Review 8.  Hsp90 and FKBP51: complex regulators of psychiatric diseases.

Authors:  Marangelie Criado-Marrero; Theo Rein; Elisabeth B Binder; James T Porter; John Koren; Laura J Blair
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-19       Impact factor: 6.237

9.  Zonda is a novel early component of the autophagy pathway in Drosophila.

Authors:  Mariana Melani; Ayelén Valko; Nuria M Romero; Milton O Aguilera; Julieta M Acevedo; Zambarlal Bhujabal; Joel Perez-Perri; Rocío V de la Riva-Carrasco; Maximiliano J Katz; Eleonora Sorianello; Cecilia D'Alessio; Gabor Juhász; Terje Johansen; María I Colombo; Pablo Wappner
Journal:  Mol Biol Cell       Date:  2017-09-13       Impact factor: 4.138

10.  Combined x-ray crystallography and computational modeling approach to investigate the Hsp90 C-terminal peptide binding to FKBP51.

Authors:  Rajnish Kumar; Martin Moche; Bengt Winblad; Pavel F Pavlov
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.